Clinical validation of a size-based microfluidic device for circulating tumor cell isolation and analysis in renal cell carcinoma
| Autor: | Palmela Leitão, Tito, Corredeira, Patrícia, Kucharczak, Sandra, Rodrigues, Margarida, Piairo, Paulina, Rodrigues, Carolina, Alves, Patrícia, Martins Cavaco, Ana Cláudia, Miranda, Miguel, Antunes, Marilia, Ferreira, João, Palma Dos Reis, José Manuel, Lopes, Tomé, Diéguez, Lorena, Costa, Luis |
|---|---|
| Přispěvatelé: | Repositório da Universidade de Lisboa |
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: |
Liquid biopsy
Circulating tumor cell Organic Chemistry Kidney cancer General Medicine Catalysis Renal cell carcinoma circulating tumor cell kidney cancer liquid biopsy microfluidic renal cell carcinoma Computer Science Applications Inorganic Chemistry Microfluidic Physical and Theoretical Chemistry Molecular Biology Spectroscopy |
| Zdroj: | International Journal of Molecular Sciences; Volume 24; Issue 9; Pages: 8404 |
| Popis: | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Renal cell carcinoma (RCC) presents as metastatic disease in one third of cases. Research on circulating tumor cells (CTCs) and liquid biopsies is improving the understanding of RCC biology and metastases formation. However, a standardized, sensitive, specific, and cost-effective CTC detection technique is lacking. The use of platforms solely relying on epithelial markers is inappropriate in RCC due to the frequent epithelial-mesenchymal transition that CTCs undergo. This study aimed to test and clinically validate RUBYchip™, a microfluidic label-free CTC detection platform, in RCC patients. The average CTC capture efficiency of the device was 74.9% in spiking experiments using three different RCC cell lines. Clinical validation was performed in a cohort of 18 patients, eight non-metastatic (M0), five metastatic treatment-naïve (M1TN), and five metastatic progressing-under-treatment (M1TP). An average CTC detection rate of 77.8% was found and the average (range) total CTC count was 6.4 (0-27), 101.8 (0-255), and 3.2 (0-10), and the average mesenchymal CTC count (both single and clustered cells) was zero, 97.6 (0-255), and 0.2 (0-1) for M0, M1TN, and M1TP, respectively. CTC clusters were detected in 25% and 60% of M0 and M1TN patients, respectively. These results show that RUBYchip™ is an effective CTC detection platform in RCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|